Newron Pharmaceuticals S.p.A. (LON: 0QOI)

Market Cap	166.07M
Revenue (ttm)	5.91M
Net Income (ttm)	-15.97M
Shares Out	n/a
EPS (ttm)	-0.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	702
Average Volume	1,301
Open	9.40
Previous Close	8.87
Day's Range	9.37 - 9.74
52-Week Range	4.12 - 10.40
Beta	0.94
RSI	64.75
Earnings Date	Apr 1, 2025

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company’s product pipeline includes Evenamide, an add-on therapy for the treatment of Schiz...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1999
• Employees: 22
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QOI

Financial Performance

In 2023, Newron Pharmaceuticals's revenue was 9.06 million, an increase of 48.62% compared to the previous year's 6.09 million. Losses were -16.22 million, -7.25% less than in 2022.

Financial numbers in EUR